| answer text |
<p>We are aware of disruptions to the supply of medicines used for the management
of attention deficit hyperactivity disorder (ADHD), primarily driven by issues which
have resulted in capacity constraints at key manufacturing sites.</p><p>The National
Patient Safety Alert to the National Health Service advises healthcare professionals
on the management of patients during this time. We have well-established processes
for managing and mitigating medicine supply issues, which involve working with the
pharmaceutical industry, the Medicines and Healthcare products Regulatory Agency,
NHS England, the devolved governments and others operating in the supply chain to
help ensure patients have access to the treatments they need.</p><p>The Department
has been working closely with the respective manufacturers and some issues have now
been resolved. However, we know that there continue to be disruptions to the supply
of some other medicines, including Xaggitin XL 18 and 36 milligrams, which are expected
to resolve in early 2024.</p>
|
|
